Digestive and Liver Disease最新文献_第10页

The IBS and SIBO dilemma: Here we go again. 肠易激综合征和 SIBO 的难题：又来了。

IF 4 3区医学

Digestive and Liver Disease Pub Date : 2024-08-31 DOI: 10.1016/j.dld.2024.08.036

Giovanni Marasco, Edoardo Vincenzo Savarino, Giovanni Barbara

引用次数: 0

Obesity and liver transplant…is it time to raise the bar? 肥胖与肝移植......是时候提高标准了吗？

IF 4 3区医学

Digestive and Liver Disease Pub Date : 2024-08-30 DOI: 10.1016/j.dld.2024.08.035

引用次数: 0

Enhancing colorectal cancer (CLC) research: Insights and areas for improvement 加强结直肠癌（CLC）研究：见解和有待改进之处。

IF 4 3区医学

Digestive and Liver Disease Pub Date : 2024-08-30 DOI: 10.1016/j.dld.2024.08.034

引用次数: 0

The workup process of vaccination in IBD patients needs a change—Insights from a multinational survey 需要改变 IBD 患者的疫苗接种工作流程--一项跨国调查的启示。

IF 4 3区医学

Digestive and Liver Disease Pub Date : 2024-08-29 DOI: 10.1016/j.dld.2024.07.031

{"title":"The workup process of vaccination in IBD patients needs a change—Insights from a multinational survey","authors":"","doi":"10.1016/j.dld.2024.07.031","DOIUrl":"10.1016/j.dld.2024.07.031","url":null,"abstract":"<div><h3>Background</h3><div>Immunosuppressive medications play a crucial role in inflammatory bowel disease (IBD) but increase susceptibility to infections, underlining the importance of vaccination. Nevertheless, vaccination rates are often low.</div></div><div><h3>Aims</h3><div>This study assessed the perspective of gastroenterologists (GEs) on vaccination of IBD patients.</div></div><div><h3>Methods</h3><div>An online survey was applied to GEs worldwide, from 10/2022 to 06/2023.</div></div><div><h3>Results</h3><div>The 271 respondents considered vaccination important, however, 26 % never/rarely prescribed vaccines and 60 % admitted having limited or no confidence on managing their side effects - GEs practicing in Europe, male and older more often felt capable of this. Female and younger participants were more aware of the need to alter the current workflow in vaccination. Some respondents proposed to delegate the responsibility of vaccination to general practitioners, nurses in gastroenterology units, or infectious diseases specialists, but 19 % considered that no change was needed.</div></div><div><h3>Conclusion</h3><div>Overall, the importance of addressing vaccine hesitancy, providing flyers to patients, and implementing vaccine guidelines were consensually recognized. The data indicated that the vaccination process needs reformulation and that different opinions/attitudes toward vaccines are influenced by demographic factors, workplace characteristics, affiliation, and teaching activities. Delegating the responsibility of vaccination and adopting a multidisciplinary approach seem like effective strategies to increase vaccination coverage among IBD patients.</div></div>","PeriodicalId":11268,"journal":{"name":"Digestive and Liver Disease","volume":null,"pages":null},"PeriodicalIF":4.0,"publicationDate":"2024-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142105398","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Full Title Page /Editorial Board 完整扉页/编辑栏

IF 4 3区医学

Digestive and Liver Disease Pub Date : 2024-08-26 DOI: 10.1016/S1590-8658(24)00899-5

引用次数: 0

Preventing recurrence after endoscopic resection for early gastric cancer: It's a long way off 预防早期胃癌内镜切除术后复发：任重而道远

IF 4 3区医学

Digestive and Liver Disease Pub Date : 2024-08-25 DOI: 10.1016/j.dld.2024.08.033

引用次数: 0

Spatial heterogeneity and prognostic significance of TAMs and TILs infiltrates in different staging esophageal squamous carcinoma. 不同分期食管鳞癌中TAMs和TILs浸润的空间异质性及其预后意义

IF 4 3区医学

Digestive and Liver Disease Pub Date : 2024-08-23 DOI: 10.1016/j.dld.2024.08.003

Ya Li, Jia Liu, Liwen Qi, Xin Yuan, Kaige Yang, Yilin Ren, Qi Shi, Guixuan Xu, Weinan Wang, Chenghua Luo, Lianghai Wang, Weihua Liang, Zengtao He, Wenhu Zhou, Jing Fei, Weigang Chen, Wenyi Gu, Feng Li, Jianming Hu

{"title":"Spatial heterogeneity and prognostic significance of TAMs and TILs infiltrates in different staging esophageal squamous carcinoma.","authors":"Ya Li, Jia Liu, Liwen Qi, Xin Yuan, Kaige Yang, Yilin Ren, Qi Shi, Guixuan Xu, Weinan Wang, Chenghua Luo, Lianghai Wang, Weihua Liang, Zengtao He, Wenhu Zhou, Jing Fei, Weigang Chen, Wenyi Gu, Feng Li, Jianming Hu","doi":"10.1016/j.dld.2024.08.003","DOIUrl":"https://doi.org/10.1016/j.dld.2024.08.003","url":null,"abstract":"<p><strong>Background: </strong>The prognostic value and clinical relevance of tumor-infiltrating lymphocytes (TILs) and tumor-associated macrophages (TAMs) in esophageal squamous cell carcinoma (ESCC) remain unclear.</p><p><strong>Aims: </strong>To investigate the prognostic value and functional involvement of TILs in ESCC.</p><p><strong>Methods: </strong>We included 40 patients across different stages of ESCC from Xinjiang. Multiplex fluorescent immunohistochemistry characterized TILs and TAMs. TILs in different tumor regions were quantified and correlated with overall survival (OS) using log-rank test and Cox regression analyses.</p><p><strong>Results: </strong>Invasive ESCC exhibited increased CD4 T cells and Tregs compared to carcinoma in situ, with a higher Tregs/CD4 T cells ratio (p < 0.05). TAMs, primarily in stromal regions, were significantly associated with Foxp3+ cells (p < 0.05). Higher infiltration of stromal TAMs and a higher CD4/CD8 T cells ratio correlated with poorer OS, while a higher CD8 T/Foxp3+ cells ratio indicated better survival. Multivariate Cox analysis revealed TNM stage, tumor length, and stromal CD4/CD8 T cells ratio as independent prognostic factors (p < 0.05). An immune prognostic risk score-based nomogram was constructed to predict patient outcomes.</p><p><strong>Conclusions: </strong>The spatial distribution and abundance of TILs significantly correlated with prognosis, providing a useful immune classification for ESCC.</p>","PeriodicalId":11268,"journal":{"name":"Digestive and Liver Disease","volume":null,"pages":null},"PeriodicalIF":4.0,"publicationDate":"2024-08-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142055174","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Rethinking ustekinumab: An essential reconsideration for moderate-to-severe Crohn's disease 反思乌司替尼：对中重度克罗恩病的必要重新考虑。

IF 4 3区医学

Digestive and Liver Disease Pub Date : 2024-08-21 DOI: 10.1016/j.dld.2024.07.032

引用次数: 0

Suboptimal outcomes of sorafenib as a second-line treatment after atezolizumab-bevacizumab for unresectable hepatocellular carcinoma. 索拉非尼作为阿特珠单抗-贝伐单抗治疗不可切除性肝细胞癌后的二线治疗方案的次优疗效。

IF 4 3区医学

Digestive and Liver Disease Pub Date : 2024-08-20 DOI: 10.1016/j.dld.2024.07.035

Francesco Tovoli, Dante Pio Pallotta, Caterina Vivaldi, Claudia Campani, Piera Federico, Andrea Palloni, Andrea Dalbeni, Caterina Soldà, Lorenzo Lani, Gianluca Svegliati-Baroni, Ingrid Garajova, Luca Ielasi, Stefania De Lorenzo, Alessandro Granito, Bernardo Stefanini, Gianluca Masi, Fabio Marra, Sara Lonardi, Giovanni Brandi, Bruno Daniele, Alessandra Auriemma, Laura Schiadà, Rusi Chen, Fabio Piscaglia

{"title":"Suboptimal outcomes of sorafenib as a second-line treatment after atezolizumab-bevacizumab for unresectable hepatocellular carcinoma.","authors":"Francesco Tovoli, Dante Pio Pallotta, Caterina Vivaldi, Claudia Campani, Piera Federico, Andrea Palloni, Andrea Dalbeni, Caterina Soldà, Lorenzo Lani, Gianluca Svegliati-Baroni, Ingrid Garajova, Luca Ielasi, Stefania De Lorenzo, Alessandro Granito, Bernardo Stefanini, Gianluca Masi, Fabio Marra, Sara Lonardi, Giovanni Brandi, Bruno Daniele, Alessandra Auriemma, Laura Schiadà, Rusi Chen, Fabio Piscaglia","doi":"10.1016/j.dld.2024.07.035","DOIUrl":"https://doi.org/10.1016/j.dld.2024.07.035","url":null,"abstract":"<p><strong>Background: </strong>Most patients receiving atezolizumab-bevacizumab (AB) for hepatocellular carcinoma will eventually experience disease progression. Randomized clinical trials (RCTs) are undergoing to identify second-line treatments. Where RCTs are unavailable or patients are non-eligible, sorafenib is often prescribed based on approval and reimbursement policies. However, evidence supporting this approach is minimal.</p><p><strong>Objective: </strong>To assess the efficacy and safety of sorafenib in patients who permanently discontinued AB.</p><p><strong>Methods: </strong>The ARTE database prospectively collects patients treated with AB in a real-life setting. We analysed the outcome of patients who received sorafenib as second-line treatment.</p><p><strong>Results: </strong>Amongst 213 patients, 130 (61.0 %) permanently discontinued AB. Of them, 54 received second- line treatments, and sorafenib was prescribed in 40 patients. The disease control rate (DCR) was 10.0 %. The median progression-free (PFS) and overall survival were 3.3 (95 % confidence interval [CI] 2.7-3.9) and 6.9 months (95 % CI 2.7-11.1), respectively.</p><p><strong>Conclusions: </strong>In patients progressing under AB, the efficacy of sorafenib on different outcomes is limited.</p>","PeriodicalId":11268,"journal":{"name":"Digestive and Liver Disease","volume":null,"pages":null},"PeriodicalIF":4.0,"publicationDate":"2024-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142016702","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Review: Risk assessment of liver and biliary cancer mortality through detection of high risk polyps at colonoscopies. 回顾：通过结肠镜检查发现高风险息肉，对肝癌和胆道癌死亡率进行风险评估。

IF 4 3区医学

Digestive and Liver Disease Pub Date : 2024-08-20 DOI: 10.1016/j.dld.2024.07.028

Abeera Tariq, Fnu Hafeezullah, Abdul Basit Khan

引用次数: 0